Karyopharm (KPTI) Chief Accounting Officer Kristin Abate Sells 19 Shares

What Happened

• Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), sold 19 shares on 2026-09-01 at $2.02 per share, generating proceeds of approximately $38.
• The sale was a disposition (open market/broker-assisted) to satisfy withholding tax obligations arising from the vesting of restricted stock units. This was not a discretionary trade by the reporting person.

Key Details

• Transaction date and price: 2026-09-01 — 19 shares @ $2.02 each.
• Total proceeds: ~ $38.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Transaction executed pursuant to a durable automatic sale instruction plan (adopted May 27, 2021); broker-assisted sale to satisfy withholding tax on RSU vesting — not a discretionary trade.
• Filing: Reported on 2026-09-02 for a 2026-09-01 transaction (appears timely).

Context

• This sale was executed solely to cover tax withholding on vested restricted stock units and therefore is routine; such transactions typically reflect tax mechanics rather than a judgment about the company’s outlook.
• For retail investors, one-off broker-assisted tax-withholding sales by insiders generally carry less informational weight than voluntary open-market purchases.